The use of attenuated Botulinium Toxin to prevent long term loss of salivary secretion in patients undergoing radiation of the head & neck for malignancies

• Conditions: Xerostomia (dry mouth) post bilateral irradation of salivary glands in the field of radiotherapy.; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Cancer - Head and neck

• Registration Number: ACTRN12612000199819
• Lead Sponsor: Royal Darwin Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

>20 years old. Existing head and neck cancer. Radiation as the primary treatment modality. Bilateral submandibular irradiation

Exclusion Criteria

No preexisting salivary gland disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Any salivary gland function (patient questionairre)[3 months post radiation]

Secondary Outcome Measures

Name	Time	Method
Clinical assesment including a sheet assessing patient's subjective perception of symptoms, and also a clinician's objective assessment.[3 months post radiation]